Buyers are jockeying for a piece of the second-biggest U.S. corporate bond sale ever, painting a picture of insatiable demand for anything with a yield. Money flowing away from exchange-traded funds (ETFs) suggests something else.
Just as Actavis Plc marketed its $21 billion bond offering on Monday to help fund its acquisition of Botox maker Allergan Inc., investors yanked $519 million from BlackRock Inc.'s iShares Core U.S. Aggregate Bond ETF.
It was the biggest daily redemption in the fund's 11-year history, and brought outflows from U.S. ETFs focused on top-rated bonds to about $2 billion in the past week, according to data compiled by Bloomberg.
Continue Reading for Free
Register and gain access to:
- Thought leadership on regulatory changes, economic trends, corporate success stories, and tactical solutions for treasurers, CFOs, risk managers, controllers, and other finance professionals
- Informative weekly newsletter featuring news, analysis, real-world case studies, and other critical content
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.